SSC
TEVA icon

Syverson Strege & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Syverson Strege & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-526
Closed -$4.66K – 558
2023
Q1 		$4.66K Buy
+526
New +$5.2K ﹤0.01% 351

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Syverson Strege & Co's TEVA Position: Q2 2023 in Review

Syverson Strege & Co sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 526 shares — an estimated $4.66K sold.

Syverson Strege & Co first reported a position in TEVA in Q1 2023 and held it in 1 quarter. The position peaked at $4.66K in Q1 2023. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Syverson Strege & Co reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 526 Teva Pharmaceuticals shares in Q2 2023, an estimated $4.66K.
  • Syverson Strege & Co first reported a position in Teva Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Syverson Strege & Co's Teva Pharmaceuticals position peaked at $4.66K in Q1 2023.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.